Success Stories

Highlights of the PCI news focused on Penn commercialization accomplishments

Updated PCI Ventures Flagship Programs announced

PCI Ventures updated its flagship programs this past year that support University startups.

Penn inventors make the mRNA-based COVID vaccines possible

Drew Weissman, MD, PhD, the Roberts Family Professor of Vaccine Research, and Katalin Karikó, PhD, an adjunct professor of Neurosurgery at Penn, have been awarded multiple prestigious prizes.

Philly just ranked high on a global list of startup ecosystems. These local leaders aren’t surprised

iladelphia landed a spot in the overall top 30 of Startup Genome's Global Startup Ecosystem Report. The city scored highest for its market reach and talent.

At-home COVID-19 results with the click of a smartphone

chers have developed a highly-sensitive rapid antigen test that can detect small loads of SARS-CoV-2

BioNTech reports promising data on mRNA cocktail in mouse models of colon cancer and melanoma

A BioNTech-led team designed a cocktail of mRNAs that instruct cells to produce four cancer-fighting molecules.

Penn scientists win $3 million Breakthrough Prize for RNA research that enabled COVID-19 vaccines

Sixteen years after their research at Penn paved the way for billions to be vaccinated against COVID-19, two scientists from Penn have been honored with the Breakthrough Prize.

Penn to play key role in the inaugural NSF Mid-Atlantic I-Corps Hub to advance entrepreneurship and technology commercialization training

PCI is proud to announce that Penn is one of the schools chosen to participate in the National Science Foundation’s new innovative I-Corps Hub initiative.

Penn mRNA researchers Drew Weissman and Katalin Karikó awarded the 2021 Albany Prize

The award, one of the largest in medicine and science in the U.S., has been given for the last 20 years by Albany Medical Center to those who have altered and positively impacted the course

COVID-19 mRNA vaccine that uses fundamental Penn technology receives FDA approval

The U.S. FDA has given the first full approval to a COVID-19 mRNA vaccine, which uses modified mRNA technology invented and developed by scientists at Penn.


Skip to content